# Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

> **NCT04656262** · PHASE3 · TERMINATED · sponsor: **Istituto Oncologico Veneto IRCCS** · enrollment: 79 (actual)

## Conditions studied

- Soft Tissue Sarcoma Adult

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT04656262
- **Lead sponsor:** Istituto Oncologico Veneto IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-10
- **Primary completion:** 2024-05-23
- **Final completion:** 2024-05-23
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** enrollment too slow to reach the target in a reasonable time frame
- **Last updated:** 2024-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04656262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04656262, "Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04656262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*